AR069007A1 - Complejos de los dominios de trpc y sestd1 y metodos y usos que envuelven los mismos - Google Patents

Complejos de los dominios de trpc y sestd1 y metodos y usos que envuelven los mismos

Info

Publication number
AR069007A1
AR069007A1 ARP080104623A ARP080104623A AR069007A1 AR 069007 A1 AR069007 A1 AR 069007A1 AR P080104623 A ARP080104623 A AR P080104623A AR P080104623 A ARP080104623 A AR P080104623A AR 069007 A1 AR069007 A1 AR 069007A1
Authority
AR
Argentina
Prior art keywords
protein
trpc
disease
test system
sestd1
Prior art date
Application number
ARP080104623A
Other languages
English (en)
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of AR069007A1 publication Critical patent/AR069007A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Complejo aislado que comprende una primera proteína que comprende o consiste en un clásico canal de potencial de receptor transitorio (TRPC) o una variante funcionalmente activa del mismo y una segunda proteína que comprende o consiste en el dominio de la primera espectrina (Spec 1) de SEC14 y los dominios 1 de espectrina (SESTD1), un sistema de prueba que comprende la primera proteína y la segunda proteína así como los medios para detectar la interacción de la primera y la segunda proteína, un método para cribar un modulador de TRPC usando el sistema y el uso del sistema de prueba para la identificación de un modulador de TRPC. Reivindicación 18: El método de cualquiera de las reivindicaciones 10 a 17, en donde el método se usa para cribar un medicamento para prevenir y/o tratar una enfermedad que envuelva la disfunción endotelial. Reivindicación 19: El método de cualquiera de las reivindicaciones 10 a 17, en donde el método se usa para cribar un medicamento para prevenir y/o tratar una enfermedad cardiovascular, hipertrofia cardiaca, fracaso del corazón, isquemia, hiperplasia neointima, cardiomiopatía dilatada idiopática, hipertensión, síndrome coronario, fracaso del corazón, fracaso del riñón, trombosis, enfermedad respiratoria crónica, asma, trastorno pulmonar obstructivo crónico, hipertensión pulmonar idiopática, vasoconstricción pulmonar hipóxica aguda, enfermedad oclusiva inflamatoria y aterosclerosis. Reivindicación 20: El uso de un sistema de prueba según la reivindicación 9 para la identificación de un modulador de TRPC.
ARP080104623A 2007-10-26 2008-10-23 Complejos de los dominios de trpc y sestd1 y metodos y usos que envuelven los mismos AR069007A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07291300A EP2053059A1 (en) 2007-10-26 2007-10-26 Complexes of TRPC domains and SESTD1 domains and methods and uses involving the same

Publications (1)

Publication Number Publication Date
AR069007A1 true AR069007A1 (es) 2009-12-23

Family

ID=39232772

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104623A AR069007A1 (es) 2007-10-26 2008-10-23 Complejos de los dominios de trpc y sestd1 y metodos y usos que envuelven los mismos

Country Status (12)

Country Link
US (1) US20100330697A1 (es)
EP (2) EP2053059A1 (es)
JP (1) JP2011501757A (es)
KR (1) KR20100076992A (es)
CN (1) CN101848933A (es)
AR (1) AR069007A1 (es)
AU (1) AU2008315951A1 (es)
CA (1) CA2702508A1 (es)
IL (1) IL205218A0 (es)
MX (1) MX2010004097A (es)
TW (1) TW200934789A (es)
WO (1) WO2009052971A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103954770B (zh) * 2014-04-25 2015-09-30 江南大学 EVs-TRPC5在检测乳腺癌耐药程度中的应用
CN110777186A (zh) * 2019-10-29 2020-02-11 浙江树人学院（浙江树人大学） Trpc1对高糖培养的内皮细胞功能影响的实验方法
CN116891523B (zh) * 2023-05-24 2024-05-17 深圳晶蛋生物医药科技有限公司 一种trpm3截短体、包含其的细胞系及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI963989A (fi) 1996-10-04 1998-04-05 Wallac Oy Homogeenisiä määritysmenetelmiä, jotka perustuvat luminesenssienergiasiirtoon
WO2001073014A1 (en) * 2000-03-24 2001-10-04 Merck Patent Gmbh Human survivin interacting protein 1 (sip-1)
US7858322B2 (en) * 2003-12-23 2010-12-28 Nono, Inc. Method of determining inhibition of binding to TRPM7 protein

Also Published As

Publication number Publication date
US20100330697A1 (en) 2010-12-30
IL205218A0 (en) 2010-11-30
EP2053059A1 (en) 2009-04-29
WO2009052971A1 (en) 2009-04-30
TW200934789A (en) 2009-08-16
JP2011501757A (ja) 2011-01-13
KR20100076992A (ko) 2010-07-06
AU2008315951A1 (en) 2009-04-30
EP2205628A1 (en) 2010-07-14
CA2702508A1 (en) 2009-04-30
MX2010004097A (es) 2010-04-30
CN101848933A (zh) 2010-09-29

Similar Documents

Publication Publication Date Title
CY1125716T1 (el) Αγωνιστες υποδοχεα glp-1 και χρησεις αυτων
CY1121695T1 (el) Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit
CY1123930T1 (el) Συνδυασμοι fgfr και cmet αναστολεων για τη θεραπεια του καρκινου
UY27965A1 (es) Derivados heterocíclicos
CY1117317T1 (el) Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων
PE20180610A1 (es) CONJUGADOS DE LIGADOR-PRINCIPIO ACTIVO (ADCs) Y CONJUGADOS DE LIGADOR-PROFARMACO (APDCs) CON GRUPOS ENZIMATICAMENTE ESCINDIBLES
NI201000034A (es) Activadores de guanilato ciclasas solubles.
IT201800009682A1 (it) Coniugati di acidi biliari e loro derivati per la veicolazione di molecole attive
EA200800356A1 (ru) Лечение ингибиторами абсорбции холестерина на основе азетидинона и омега-3 жирными кислотами и их комбинированным препаратом
CR20110032A (es) Derivados de tiofeno y tiazol y su uso como inhibidores de p13k
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
CR10024A (es) Ligandos que tienen espeficidad de enlace para egfr y/ o vegf, y métodos de uso de los mismos
CO6430463A2 (es) Activadores de guanilato ciclasa solubles
ATE516285T1 (de) Dihydropyridinonderivate
CY1116111T1 (el) Τοπικη συνθεση για τη θεραπεια της ακτινικης κερατωσης
CO6260094A2 (es) Anticuerpos novedosos anti-alpha5beta1 y usos de los mismos
PE20141019A1 (es) Nuevos inmunoconjugados
CY1112813T1 (el) 4-(4-κυανο-2-θειοαρυλ)διϋδροπυριμιδινονες και η χρηση αυτων
CY1113314T1 (el) (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης
CY1114153T1 (el) Παραγωγα κυκλοαλκανοπυρρολοκαρβαzολιου και η χρηση αυτων ως αναστολεις parp, vegfr2 και mlk3
CL2008002478A1 (es) Compuestos derivados de n-fenil-5-(4 haloalcoxi)fenil) pirimidin-2-amino, inhibidores de c-kit y pdgfr; composicion farmaceutica; y su uso en el tratmiento de asma, dermatitis atopica, hipertension pulmonar o arterial, fibrosis renal, pulmonar o cardiaca, entre otras.
PA8651301A1 (es) Nuevas piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)
CY1113651T1 (el) Αντιφλεγμονωδη σκευασματα
CY1117654T1 (el) Πολυαιθυλενογλυκολιωμενη απελινη και χρησεις αυτης
CY1119999T1 (el) Καινοτομος συνθεση για τη θεραπευτικη αντιμετωπιση της κυστικης ινωσης

Legal Events

Date Code Title Description
FB Suspension of granting procedure